News & Updates
Filter by Specialty:
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
In patients with high-risk or unfavourable nonmetastatic prostate cancer (nmPC) receiving local definite therapy, the intensification of systemic therapy using chemotherapy or an androgen receptor signaling inhibitor (ARSI), in combination with androgen deprivation therapy (ADT), leads to better oncologic survival measures, reports a recent meta-analysis.
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
Treatment with the combination of ramucirumab and paclitaxel in the second-line setting appears to yield higher responses among patients with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma than among those with HER2-negative disease, according to a subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
26 Apr 2022
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
Use of low-dose aspirin appears to have a null effect on the 5-year survival of patients who undergo gastrectomy for gastric adenocarcinoma, a study reports.
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
24 Apr 2022
Circulating antioxidants play no protective role in breast, ovarian cancers
Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.
Circulating antioxidants play no protective role in breast, ovarian cancers
23 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
Larger tumours tied to prostate cancer biochemical recurrence
In patients with localized prostate cancer (PCa), higher tumour volume (TV) appears to cut biochemical recurrence-free survival short, a recent study has found.
Larger tumours tied to prostate cancer biochemical recurrence
22 Apr 2022
SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
